绥美凯（多替阿巴拉米片）是什么？

(Dolutea Paramid Tablets) was approved for marketing by the FDA on August 27, 2014. On January 20, 2018, ViiV, a joint venture of GlaxoSmithKline, the first drug with a complete antiviral treatment program centered on dolutegravir (also known as DTG in English), Suimeike (dolutea abalamib tablets), was officially launched in China. This is also the first complete single-pill compound treatment program in the field of HIV treatment in China. Suimeikai (dolute abalamide tablets) is composed of three ingredients: DTG (DTG) + abacavir (ABC) + lamivudine (3TC). It is a compound treatment agent of integrase inhibitors and nucleoside drugs. Today let’s find out what Suimeikai (Doteta Abalamid Tablets) is?

In 2016, GSK announced the launch of the integrase DTG (Trivic) in China. This therapeutic agent has the advantages of small drug dosage, low resistance to drug resistance, and low probability of drug side effects. This time, Trimax (doteta abalamib tablets) is based on DTG, an integrase inhibitor, as the core drug. It is combined with a treatment plan of two backbone drugs, abacavir and lamivudine, and is made into a single-tablet treatment for promotion, making the core drug a great progress in HAART treatment. In addition, this treatment agent can significantly reduce the medication burden of AIDS patients, thereby improving patients' medication compliance and effectively improving the patients' quality of life and work.

Suimeike (dolute abalamib tablets) is suitable for the treatment of adults and adolescents over 12 years old (with a weight of at least 40 kg) infected with human immunodeficiency virus (HIV). In terms of taking: Suimeikai (dolute abalamib tablets) should be taken under the guidance of a physician with experience in the treatment of HIV infection. Adults and Adolescents (Weighing at least 40 kg) For adults and adolescents, the recommended dose is one tablet once daily. Adults or adolescents whose body weight is less than 40 kg should not be given as this product is a fixed-dose tablet and the dose cannot be reduced.

Trimax (dolutegravir) should not be used in patients who require dose adjustments. If one of the active ingredients needs to be discontinued or a dose adjustment is required, a separate formulation of dolutegravir, abacavir, or lamivudine may be used. In these cases, the physician should refer to the respective product information for these medicines. If a patient misses a dose of this product and it is more than 4 hours before the next dose, the drug should be taken as soon as possible. If the next dose is less than 4 hours away, the patient should not take the missed dose and simply resume the usual dosing schedule.

The above is the content of the drug introduction of (Doteta Abalami Tablets), I hope it can help you!